UY35678A - SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO - Google Patents

SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO

Info

Publication number
UY35678A
UY35678A UY35678A UY35678A UY35678A UY 35678 A UY35678 A UY 35678A UY 35678 A UY35678 A UY 35678A UY 35678 A UY35678 A UY 35678A UY 35678 A UY35678 A UY 35678A
Authority
UY
Uruguay
Prior art keywords
activity
hydroxyquinolin
derivatives
agenist
adrenerical
Prior art date
Application number
UY35678A
Other languages
English (en)
Inventor
Francesc Carrera Carrera
Francesca Pajuelo Lorenzo
Maria Prat Quiñones
Montserrat Julia Jane
Carlos Puig Duran
Juan Antonio Perez Andres
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48917474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY35678(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY35678A publication Critical patent/UY35678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a sales de adición cristalinas de (i) derivados de 8-hidroxiquinolin-2(1H)-ona y (ii) un ácido dicarboxílico, un ácido sulfónico o una sulfimida, o un solvato farmacéuticamente aceptable de las mismas.
UY35678A 2013-07-25 2014-07-25 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO UY35678A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382304 2013-07-25

Publications (1)

Publication Number Publication Date
UY35678A true UY35678A (es) 2015-02-27

Family

ID=48917474

Family Applications (1)

Application Number Title Priority Date Filing Date
UY35678A UY35678A (es) 2013-07-25 2014-07-25 SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO

Country Status (36)

Country Link
US (1) US9579316B2 (es)
EP (1) EP3024489B1 (es)
JP (1) JP6374962B2 (es)
KR (1) KR102338155B1 (es)
CN (2) CN112321579A (es)
AR (1) AR097079A1 (es)
AU (1) AU2014295028B2 (es)
BR (1) BR112016001295B1 (es)
CA (1) CA2917596C (es)
CL (1) CL2016000187A1 (es)
CR (1) CR20160043A (es)
CY (1) CY1122920T1 (es)
DK (1) DK3024489T3 (es)
DO (1) DOP2016000011A (es)
EA (1) EA035436B1 (es)
ES (1) ES2788627T3 (es)
HK (1) HK1219043A1 (es)
HR (1) HRP20200670T1 (es)
HU (1) HUE049441T2 (es)
IL (1) IL243173B (es)
LT (1) LT3024489T (es)
MX (1) MX360837B (es)
MY (1) MY184681A (es)
NI (1) NI201600012A (es)
NZ (1) NZ715128A (es)
PE (1) PE20160173A1 (es)
PH (1) PH12016500125A1 (es)
PL (1) PL3024489T3 (es)
PT (1) PT3024489T (es)
RS (1) RS60185B1 (es)
SG (1) SG11201510682YA (es)
SI (1) SI3024489T1 (es)
TW (1) TWI641373B (es)
UY (1) UY35678A (es)
WO (1) WO2015011244A1 (es)
ZA (1) ZA201509203B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
EP3607941A1 (en) 2013-04-30 2020-02-12 Otitopic Inc. Dry powder formulations and methods of use
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
EP3375781A4 (en) * 2015-07-21 2019-01-09 Sichuan Haisco Pharmaceutical Co., Ltd. BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE
CN106554350B (zh) * 2015-09-29 2019-12-20 四川海思科制药有限公司 具有β2激动活性的苯并杂环衍生物及其制法和应用
TW201835041A (zh) * 2017-02-17 2018-10-01 印度商托仁特生技有限公司 具β-腎上腺素促效劑及抗蕈毒活性化合物
AU2017432640B2 (en) 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2020244452A1 (zh) * 2019-06-06 2020-12-10 中国医药研究开发中心有限公司 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途
CN116457357A (zh) * 2020-09-28 2023-07-18 正大天晴药业集团股份有限公司 稠合的三并环衍生物及其在药学上的应用
WO2023179758A1 (zh) * 2022-03-25 2023-09-28 正大天晴药业集团股份有限公司 稠合三并环衍生物或其可药用盐的结晶

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1212742B (it) 1983-05-17 1989-11-30 Dompe Farmaceutici Spa Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica
DE3370320D1 (en) 1983-09-26 1987-04-23 Magis Farmaceutici Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
EP1078629A3 (en) 1989-09-07 2001-05-23 Glaxo Group Limited Use of Salmeterol and salts for the treatment of inflammation and allergy
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
AU4248597A (en) 1996-09-06 1998-03-26 Merck & Co., Inc. Methods and compositions for treating preterm labor
SE9704644D0 (sv) 1997-12-12 1997-12-12 Astra Ab New use
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
TR200200409T2 (tr) 1999-08-20 2003-03-21 Dow Agrosciences Llc Mantar öldürücü heterosiklik aromatik amitler ve bileşimleri, bunları kullanma ve hazırlama yöntemleri.
US6806314B2 (en) 2003-02-03 2004-10-19 Ppg Industries Ohio, Inc. Coating of Hydroxy-functional polymer(s), crosslinker, and 1,3- and 1,4-cyclohexane dimethanols
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7358244B2 (en) 2003-05-28 2008-04-15 Theravance, Inc. Azabicycloalkane compounds
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
ES2251867B1 (es) 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
CA2643097C (en) 2006-03-20 2012-03-13 Pfizer Limited Amine derivatives
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
EA200900337A1 (ru) 2006-10-04 2009-10-30 Пфайзер Лимитед Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов
GB0700972D0 (en) 2007-01-18 2007-02-28 Imp Innovations Ltd Treatment of inflammatory disease
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
UY31235A1 (es) 2007-07-21 2009-03-02 Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
PL2242759T3 (pl) 2008-02-06 2013-06-28 Astrazeneca Ab Związki
CN101544572B (zh) 2008-03-26 2013-03-20 连云港恒邦医药科技有限公司 一种氨溴索衍生物及其制备方法
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
JP2011524897A (ja) * 2008-06-20 2011-09-08 アストラゼネカ・アクチエボラーグ β２−アドレナリン受容体活性の調節のための、４−ヒドロキシ−２−オキソ−２，３−ジヒドロ−１，３−ベンゾチアゾール−７−イル化合物を含む医薬組成物
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
SI3210981T1 (sl) 2009-04-23 2019-05-31 Theravance Respiratory Company, Llc Diamidne spojine, ki imajo muskarinsko receptorsko antagonistično in beta 2 adrenergično receptorsko agonistično aktivnost
US9072734B2 (en) 2009-04-30 2015-07-07 Teijin Pharma Limited Quaternary ammonium salt compounds
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
GB201002612D0 (en) * 2010-02-16 2010-03-31 Jagotec Ag Improvements in or relating to organic compounds
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
KR101906630B1 (ko) 2011-06-10 2018-10-10 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP5731718B2 (ja) 2011-11-11 2015-06-10 ファイザー・インク ２−チオピリミジノン
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA116622C2 (uk) 2011-11-11 2018-04-25 Аллерган, Інк. Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей
LT3329919T (lt) 2011-11-11 2020-02-10 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
EA030552B1 (ru) 2012-12-06 2018-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
CA2893627C (en) 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
TW201440768A (zh) 2013-02-27 2014-11-01 Almirall Sa 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Also Published As

Publication number Publication date
WO2015011244A1 (en) 2015-01-29
AU2014295028A1 (en) 2016-01-21
EA035436B1 (ru) 2020-06-15
KR102338155B1 (ko) 2021-12-10
CL2016000187A1 (es) 2016-08-05
ZA201509203B (en) 2017-04-26
JP6374962B2 (ja) 2018-08-15
CA2917596A1 (en) 2015-01-29
PT3024489T (pt) 2020-05-05
DOP2016000011A (es) 2016-06-15
NI201600012A (es) 2016-10-10
JP2016525533A (ja) 2016-08-25
CR20160043A (es) 2016-04-08
IL243173B (en) 2019-10-31
CY1122920T1 (el) 2021-10-29
TWI641373B (zh) 2018-11-21
EP3024489B1 (en) 2020-02-19
LT3024489T (lt) 2020-03-10
RS60185B1 (sr) 2020-06-30
IL243173A0 (en) 2016-02-29
MX2016000397A (es) 2016-04-29
PE20160173A1 (es) 2016-04-13
HUE049441T2 (hu) 2020-09-28
AR097079A1 (es) 2016-02-17
CN112321579A (zh) 2021-02-05
BR112016001295A2 (es) 2017-07-25
MX360837B (es) 2018-11-20
DK3024489T3 (da) 2020-05-04
CN105492027A (zh) 2016-04-13
AU2014295028B2 (en) 2018-05-31
SI3024489T1 (sl) 2020-04-30
PH12016500125B1 (en) 2016-04-25
PH12016500125A1 (en) 2016-04-25
KR20160034310A (ko) 2016-03-29
PL3024489T3 (pl) 2020-08-10
MY184681A (en) 2021-04-16
NZ715128A (en) 2019-03-29
CA2917596C (en) 2021-06-22
SG11201510682YA (en) 2016-02-26
BR112016001295B1 (pt) 2022-07-19
ES2788627T3 (es) 2020-10-22
HRP20200670T1 (hr) 2020-07-10
EA201600128A1 (ru) 2016-07-29
TW201517907A (zh) 2015-05-16
US9579316B2 (en) 2017-02-28
US20160166566A1 (en) 2016-06-16
EP3024489A1 (en) 2016-06-01
HK1219043A1 (zh) 2017-03-24

Similar Documents

Publication Publication Date Title
UY35678A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD ANTAGO NISTA DE RECEPTORES MUSCARÍNICOS ASÍ COMO ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO
UY35355A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONIS TA DEL RECEPTOR ß2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M3.
CY1123427T1 (el) Kpyσtaλλikeς mopφeς δiamopφωτη yποδoxea anδpoγonωn
ECSP18010481A (es) Composiciones de plinabulina
CO7180199A2 (es) Imidazotriazincarbonitrilos útiles como inhibidores de cinasa
CR20150265A (es) Formas de dosificación de ruxolitinib de liberación sostenida
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
BR112015023161A8 (pt) derivados de piridin-4-ila
UY35320A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA SUSTITUIDA CON HETEROARILO?.
DOP2011000382A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
CO2019001644A2 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CL2017002605A1 (es) Derivados de indol
DOP2016000062A (es) Derivados de indol-urea de glucopiranosil sustituido y su uso como inhibidores de sglt
SV2015005045A (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M3
ECSP15025357A (es) Formas de dosificación de ruxolitinib de liberación sostenida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20211207